ClinicalTrials.gg
Not yet recruitingNCT07330817ULTRAVIOLETFIMUpdated Oct 20, 2026

A First-In-Man Study to Assess Safety and Efficacy of Ultra High Pressure PTA Balloon ULTRAVIOLET in Treating A-V Fistula Stenosis

An interventional study of PTA balloon in Arterio-venous Fistula and Stenosis of Arteriovenous Dialysis Fistula, sponsored by Cardionovum GmbH. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Cardionovum GmbH · Not applicable, Interventional, and Treatment

How we know

Updated Oct 20, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

First-In-Man Single Arm Prospective Study to assess the safety and efficacy of ULTRAVIOLET UHP PTA balloon.

Read the detailed description

First-In-Man Single Site study to assess safety and efficacy of ultra-high pressure PTA balloon called ULTRAVIOLET UHP PTA in treating resistant stenotic lesions in arterio-venous fistula of dialysis patients.

02

Conditions studied

  • Arterio-venous Fistula
  • Stenosis of Arteriovenous Dialysis Fistula

Browse trials for

Keywords

  • A-V fistula
  • First-In-Man
  • Ultra-High Pressure Balloon
  • PTA balloon
  • Resistant Stenotic Fistula
03

In context

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

This study's planned enrollment of 35 is below the median of 64 across 166 interventional studies indexed under Arteriovenous Fistula.

Browse Arteriovenous Fistula studies →

Lead sponsor

Cardionovum GmbH is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients able to understand the purpose of the study, voluntarily agree to participate and signed form
  • Patients with impaired haemodialysis access due to narrowed lesions, as indicated by contrast or ultrasound or clinical diagnosis.
  • Indications for percutaneous endovascular therapy with diameter stenosis >50% and fistula's hemodynamic showing abnormalities (thrombosis in the AVF, high venous pressure, re-circulation, abnormal physical examination, decrease in dialysis efficiency, decrease in blood flow through the vascular access)
  • Target lesion is a resistant de novo or restenotic lesion
  • The target lesion is located in the reflux vein from the anastomotic site of arteriovenous fistula (AVF) to the distal end of the subclavian vein (excluding the anastomotic site of AVF); if there are no target lesions, they should be treated with standard angioplasty balloon before treating the target lesion.

Exclusion criteria

Exclusion Criteria:

  • Female of , unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrolment into this study;
  • Patients who are actively participating in another drug or device study, who have not completed the primary endpoint follow-up period;
  • Patients who have undergone major surgical procedures (such as open chest surgery, head surgery) within 30 days before being enrolled in the study;
  • Patients who plan to undergo major surgical procedures (such as open chest surgery, head surgery) within 30 days after being enrolled in the study;
  • Immature AVF (not used for dialysis; due to insufficient inner diameter, inability to ensure successful puncture, and inadequate blood flow, this access has not been used for successful dialysis);
  • AVF has been implanted with a stent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    ULTRAVIOLET UHP PTA

    Percutaneous transluminal angioplasty with ultra-high-pressure balloon

    Device: PTA balloon

Interventions

  • DevicePTA balloon

    Angioplasty of a resistant stenotic lesion in the arterio-venous fistula

06

What researchers measure

Primary outcomes

  1. Technical Success

    Ability to cross the lesion and fully efface the balloon, leaving no residual stenosis (\<30%) evaluated by fistulography

    Time frame: At the end of the procedure (up to 40 minutes)

  2. Freedom from procedure-related complications after 1 month

    freedom from adverse events related to the procedure in 1 month follow up period

    Time frame: 1 month

Secondary outcomes

  1. Acute Device Success

    successful delivery, balloon inflation, deflation, and retrieval of the intact study device without burst below rated burst pressure

    Time frame: At the end of the procedure (up to 40 minutes)

  2. Clinical Success

    after intervention, the function of hemodialysis access is improved, dialysis function is restored, and at least one complete dialysis session has been completed

    Time frame: At the end of the procedure (up to 40 minutes)

  3. Procedural Surgery success

    Once technical success has been achieved, no major adverse events (MAE) occurred during the procedure or hospitalization, including death, stroke, thrombosis, allergic reactions, or pulmonary disease

    Time frame: At the end of hospitalization (assessed up to 5 days)

  4. Target Lesion Primary Patency

    Primary patency rate refers to the peak systolic velocity ratio (PSVR) measured by Doppler ultrasound (DUS) ≤ 2.0, which confirms the absence of restenosis and does not require clinically driven target lesion revascularization (CD-TLR)

    Time frame: 1 month

  5. Freedom from target lesion revascularization

    Clinical symptoms and dialysis indicators indicate that dialysis cannot be successfully performed, and the target lesion location (confirmed by Doppler ultrasound) +/-5 mm proximal/distal requires re-intervention surgery

    Time frame: 1 month

  6. Major Adverse Events (MAE)

    Occurrence of major adverse events (MAE)

    Time frame: 1 month

  7. Dialysis Circuit Patency

    Patency of the whole patency circuit evaluated at Doppler Ultra-Sound (DUS)

    Time frame: 1 month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 84 interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 12 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Feb 2026 → Jan 2027, primary completion Jan 2027 → Jan 2028 and completion Feb 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Jan 9, 2026
StartEst.
Jan 2027was Feb 2026
Primary completionEst.
Jan 2028was Jan 2027
CompletionEst.
Feb 2028was Feb 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 2026→Jan 2027
Oct 20, 2026
Primary completion
Jan 2027→Jan 2028
Oct 20, 2026
Study completion
Feb 2027→Feb 2028
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Feb 2026→Jan 2027
    Primary completion Jan 2027→Jan 2028
    Study completion Feb 2027→Feb 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07330817
Lead sponsor
Cardionovum GmbH
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Paolo Silvestri, MSc
Contact
paolo.silvestri@cardionovum.com
+393451016383
Matteo Tozzi, MD, PhD
principal investigator · Universita' Insubria, ASST Sette Laghi, Varese, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion